Loading...
Please wait, while we are loading the content...
Similar Documents
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B
| Content Provider | Scilit |
|---|---|
| Author | Vassiliadis, T. Nikolaidis, N. Giouleme, O. Tziomalos, K. Grammatikos, N. Patsiaoura, K. Zezos, P. Gkisakis, D. Theodoropoulos, K. Katsinelos, P. Orfanou-Koumerkeridou, E. Eugenidis, N. |
| Copyright Year | 2005 |
| Description | Journal: Alimentary Pharmacology & Therapeutics Background : Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance. The role of adefovir dipivoxil in these patients has not been definitively evaluated. Aim : To address the role of adefovir in the management of patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Methods : Patients were assigned to receive adefovir 10 mg once daily plus ongoing lamivudine 100 mg once daily for 52 weeks. The primary end point was reduction in serum hepatitis B virus DNA level (hepatitis B virus DNA response). Secondary end points included the proportion of patients with undetectable hepatitis B virus DNA at week 52 (complete virological response) and the percentage of patients with normalization of alanine transferase level at week 52 (biochemical response). Results : A total of 49 consecutive patients were enrolled in this study. After 52 weeks of treatment, all patients had an hepatitis B virus DNA response and 57.1% had complete virological response. Biochemical response occurred in 75.6% of patients. Conclusions : Administration of adefovir in patients with lamivudine-resistant chronic hepatitis B results in significant suppression of viral replication. Nevertheless, continuous therapy will probably be needed in order to maintain remission in these patients. |
| Related Links | https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2005.02388.x |
| Ending Page | 537 |
| Page Count | 7 |
| Starting Page | 531 |
| e-ISSN | 13652036 |
| DOI | 10.1111/j.1365-2036.2005.02388.x |
| Journal | Alimentary Pharmacology & Therapeutics |
| Issue Number | 5 |
| Volume Number | 21 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2005-03-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Alimentary Pharmacology & Therapeutics Gastroenterology and Hepatology Viral Replication Hepatitis B Virus Chronic Hepatitis Virus Dna Lamivudine Resistant |
| Content Type | Text |
| Resource Type | Article |
